The global cardiovascular drugs market size is expected to reach around US$ 92.3 Bn by 2026 and growing at a CAGR of around 2.3% over the forecast period 2019 to 2026.
Cardiovascular drugs offer effective treatment and have curiosity to enhance treatment outcomes, enhance patient compliance with prescriptions and eliminate the need for insurers to pay for expensive but ineffective therapies. These types of drugs offers beneficial to patients and can outweigh any potential serious side effects or risks. The cardiovascular drugs include transferring of genetic material into a host cell through Anti-Hyperlipidemics, Anti-Hypertensive and manipulation of the tumor microenvironment, to reduce tumor vasculature. The main function of cardiovascular drugs is regeneration or replacement of mutated genes with healthy genes. Based on drugs type, different types of cardiovascular drugs such as anti-hyperlipidemics, anti-hypertensive, anti-coagulants, anti-arrhythmic, anti-fibrinolytic, and others are used.
Market Dynamics
The growth of the cardiovascular drugs market is primarily driven by the rising prevalence of chronic disease, increase in geriatric population across the globe, and technological advancements in cardiovascular drugs. Furthermore, increase in demand and preference for non-invasive treatment and expanding base of cancer patients worldwide and increase in number of diabetic patients, is estimated to boost the market growth. Moreover, changing lifestyles of consumers across developed countries, growing pharmaceutical and medical industry, technological advancement and increase in the number of applications are expected to create opportunities for the manufacturers in the global market over the forecast period. However, stringent government regulations and side effects of drugs are expected to hamper the growth of the global cardiovascular drugs market in the coming years.
By drug type, anti-coagulants segment dominated the cardiovascular drugs market
The anti-coagulants segment accounted for approximately 34% of the share in the global cardiovascular drugs market in 2018. Increase in demand for treatment in blood cancer, effective than other drugs, creating and modification of cells outside body to increase the stability of treatment, and rising incidences of various diseases is further expected to raise segment over the forecast period.
By distribution channel, hospitals segment dominated the cardiovascular drugs market
The hospitals segment accounted for approximately 31% of the share in the global cardiovascular drugs market in 2018. Growing demand for multi-specialty treatment and devices and cataract procedures and growing consumer preference towards technology advanced surgical procedures performed in hospitals, and medications are prescribed after treatment in hospitals is further expected to raise segment over the forecast period. Owing to its growing number of surgery, growing number of devices requirement in hospitals, and supportive government initiatives for cardiovascular drugs in hospitals further grows the demand for cardiovascular drugs in hospitals applications during the forecast period.
By disease indication, hypertension segment dominated the cardiovascular drugs market
The hypertension segment accounted for approximately 34% of the share in the global cardiovascular drugs market in 2018. Rise in number of hypertension patient and increase in cancer and diabetes population across the globe. Geriatric population across the globe and growing incidence of cataract, and rising demand for preventive checkup is further expected to raise segment over the forecast period.
The market research study on “Cardiovascular Drugs Market– Global Industry Analysis, Market Size, Opportunities and Forecast, 2019 – 2026”,offers a detailed insight into the global cardiovascular drugs market entailing insights on its different market segments. Market dynamics with drivers, restraints, and opportunities with their impact are provided in the report. The report provides insights into the global cardiovascular drugs market, its drug type, disease indication, distribution channel, and major geographic regions. The report covers basic development policies and layouts of technology development processes. Secondly, the report covers global cardiovascular drugs market size, and segment markets by drug type, disease indication, distribution channel, and geography along with the information on companies operating in the market. The cardiovascular drugs market analysis is provided for major regional markets including North America, Europe, Asia Pacific, Latin America and Middle East and Africa. For each region, the market size for different segments has been covered under the scope of the report.
In 2018, North America dominated the regional market with a maximum market share
North America accounted for the high market share of the cardiovascular drugs market and the region is also expected to maintain its dominance over the forecast period. The region is experiencing the maximum growth owing to the rapid consumption of cardiovascular drugs in various end user applications, presence of cardiovascular drugs companies, favorable reimbursement policies, and rapidly growing diabetic population. Highly efficient reimbursement structure and developed healthcare infrastructure in the North America region is one of the key factors driving the consumption of cardiovascular drugs in this region. Moreover, highly skilled neurosurgeons, growing number of hospitals and research centers in key countries such as US and Canada are also propelling the growth of cardiovascular drugs in the North America region. Europe is followed by the North America region in the cardiovascular drugs market.
Asia-Pacific is expected to hold the highest CAGR in the global market during the forecast period. The growing prevalence of cancer, increase in innovation and development in cardiovascular drugs, and growing geriatric populations, are expected to enhance the market growth in the global cardiovascular drugs market during the forecast.
The players profiled in the report include Novartis AG, Bayer AG, Pfizer Inc., Merck and Co. Inc., Johnson & Johnson, Eli Lilly and Company, Takeda Pharmaceutical Company Ltd, Otsuka Holdings Co., Ltd., Gilead Sciences Inc., Sun Pharma Industries, and Abbott Laboratories among others. The companies are involved in mergers and acquisitions and new product development for expanding their market share and also for gaining competitive advantages over its competitors.
Market Segmentation
Market By Drug Type
- Anti-Hyperlipidemics
- Anti-Hypertensive
- Anti-Coagulants
- Anti-Arrhythmic
- Anti-Fibrinolytic
- Others
Market By Disease Indication
- Hypertension
- Hyperlipidemia
- Coronary Artery Disease
- Others
Market By Distribution Channel
- Hospitals Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Others
Market By Geography
North America
Europe
- U.K.
- Germany
- France
- Spain
- Rest of Europe
Asia-Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Mexico
- Rest of Latin America
Middle East & Africa
- GCC
- South Africa
- Rest of Middle East & Africa
Table Of Content:
CHAPTER 1. INDUSTRY OVERVIEW
1.1. Definition and Scope
1.1.1. Definition of Cardiovascular Drugs
1.1.2. Market Segmentation
1.1.3. List of Abbreviations
1.2. Summary
1.2.1. Market Snapshot
1.2.2. Cardiovascular Drugs Market By Drug Type
1.2.2.1. Global Cardiovascular Drugs Market Revenue and Growth Rate Comparison By Drug Type (2015-2026)
1.2.2.2. Global Cardiovascular Drugs Market Revenue Share By Drug Type in 2018
1.2.2.3. Anti-Hyperlipidemics
1.2.2.4. Anti-Hypertensive
1.2.2.5. Anti-Coagulants
1.2.2.6. Anti-Arrhythmic
1.2.2.7. Anti-Fibrinolytic
1.2.2.8. Others
1.2.3. Cardiovascular Drugs Market By Disease Indication
1.2.3.1. Global Cardiovascular Drugs Market Revenue and Growth Rate Comparison By Disease Indication (2015-2026)
1.2.3.2. Global Cardiovascular Drugs Market Revenue Share By Disease Indication in 2018
1.2.3.3. Hypertension
1.2.3.4. Hyperlipidemia
1.2.3.5. Coronary Artery Disease
1.2.3.6. Others
1.2.4. Cardiovascular Drugs Market By End-Use
1.2.4.1. Global Cardiovascular Drugs Market Revenue and Growth Rate Comparison By End-Use (2015-2026)
1.2.4.2. Global Cardiovascular Drugs Market Revenue Share By End-Use in 2018
1.2.4.3. Hospitals Pharmacies
1.2.4.4. Retail Pharmacies
1.2.4.5. Online Pharmacies
1.2.4.6. Others
1.2.5. Cardiovascular Drugs Market By Geography
1.2.5.1. Global Cardiovascular Drugs Market Revenue and Growth Rate Comparison by Geography (2015-2026)
1.2.5.2. North America Cardiovascular Drugs Market Revenue and Growth Rate (2015-2026)
1.2.5.3. Europe Cardiovascular Drugs Market Revenue and Growth Rate (2015-2026)
1.2.5.4. Asia-Pacific Cardiovascular Drugs Market Revenue and Growth Rate (2015-2026)
1.2.5.5. Latin America Cardiovascular Drugs Market Revenue and Growth Rate (2015-2026)
1.2.5.6. Middle East and Africa (MEA) Cardiovascular Drugs Market Revenue and Growth Rate (2015-2026)
CHAPTER 2. MARKET DYNAMICS AND COMPETITION ANALYSIS
2.1. Market Drivers
2.2. Restraints and Challenges
2.3. Growth Opportunities
2.4. Porter’s Five Forces Analysis
2.4.1. Bargaining Power of Suppliers
2.4.2. Bargaining Power of Buyers
2.4.3. Threat of Substitute
2.4.4. Threat of New Entrants
2.4.5. Degree of Competition
2.5. Value Chain Analysis
2.6. Cost Structure Analysis
2.6.1. Raw Material and Suppliers
2.6.2. Manufacturing Process Analysis
2.7. Regulatory Compliance
2.8. Competitive Landscape, 2018
2.8.1. Player Positioning Analysis
2.8.2. Key Strategies Adopted By Leading Players
CHAPTER 3. MANUFACTURING PLANTS ANALYSIS
3.1. Capacity and Commercial Production Date of Global Cardiovascular Drugs Major Manufacturers in 2018
3.2. Manufacturing Plants Distribution of Global Cardiovascular Drugs Major Manufacturers in 2018
3.3. R&D Status and Technology Source of Global Cardiovascular Drugs Major Manufacturers in 2018
3.4. Raw Materials Sources Analysis of Global Cardiovascular Drugs Major Manufacturers in 2018
CHAPTER 4. CARDIOVASCULAR DRUGS MARKET By DRUG TYPE
4.1. Global Cardiovascular Drugs Revenue By Drug Type
4.2. Anti-Hyperlipidemics
4.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.3. Anti-Hypertensive
4.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.4. Anti-Coagulants
4.4.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.4.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.5. Anti-Arrhythmic
4.5.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.5.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.6. Anti-Fibrinolytic
4.6.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.6.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.7. Others
4.7.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.7.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
CHAPTER 5. CARDIOVASCULAR DRUGS MARKET BY DISEASE INDICATION
5.1. Global Cardiovascular Drugs Revenue By Disease Indication
5.2. Hypertension
5.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.3. Hyperlipidemia
5.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.4. Coronary Artery Disease
5.4.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.4.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.5. Others
5.5.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.5.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
CHAPTER 6. CARDIOVASCULAR DRUGS MARKET BY END-USE
6.1. Global Cardiovascular Drugs Revenue By End-Use
6.2. Hospitals Pharmacies
6.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
6.3. Retail Pharmacies
6.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
6.4. Online Pharmacies
6.4.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.4.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
6.5. Others
6.5.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.5.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
CHAPTER 7. NORTH AMERICA CARDIOVASCULAR DRUGS MARKET BY COUNTRY
7.1. North America Cardiovascular Drugs Market Revenue and Growth Rate, 2015 - 2026 ($Million)
7.2. North America Cardiovascular Drugs Market Revenue Share Comparison, 2015 & 2026 (%)
7.3. U.S.
7.3.1. U.S. Cardiovascular Drugs Market Revenue and Forecast By Drug Type, 2015 - 2026 ($Million)
7.3.2. Market Revenue and Forecast By Disease Indication, 2015 - 2026 ($Million)
7.3.3. Market Revenue and Forecast By End-Use, 2015 - 2026 ($Million)
7.4. Canada
7.4.1. Market Revenue and Forecast By Drug Type, 2015 - 2026 ($Million)
7.4.2. Market Revenue and Forecast By Disease Indication, 2015 - 2026 ($Million)
7.4.3. Market Revenue and Forecast By End-Use, 2015 - 2026 ($Million)
CHAPTER 8. EUROPE CARDIOVASCULAR DRUGS MARKET BY COUNTRY
8.1. Europe Cardiovascular Drugs Market Revenue and Growth Rate, 2015 - 2026 ($Million)
8.2. Europe Cardiovascular Drugs Market Revenue Share Comparison, 2015 & 2026 (%)
8.3. UK
8.3.1. Market Revenue and Forecast By Drug Type, 2015 - 2026 ($Million)
8.3.2. Market Revenue and Forecast By Disease Indication, 2015 - 2026 ($Million)
8.3.3. Market Revenue and Forecast By End-Use, 2015 - 2026 ($Million)
8.4. Germany
8.4.1. Market Revenue and Forecast By Drug Type, 2015 - 2026 ($Million)
8.4.2. Market Revenue and Forecast By Disease Indication, 2015 - 2026 ($Million)
8.4.3. Market Revenue and Forecast By End-Use, 2015 - 2026 ($Million)
8.5. France
8.5.1. Market Revenue and Forecast By Drug Type, 2015 - 2026 ($Million)
8.5.2. Market Revenue and Forecast By Disease Indication, 2015 - 2026 ($Million)
8.5.3. Market Revenue and Forecast By End-Use, 2015 - 2026 ($Million)
8.6. Spain
8.6.1. Market Revenue and Forecast By Drug Type, 2015 - 2026 ($Million)
8.6.2. Market Revenue and Forecast By Disease Indication, 2015 - 2026 ($Million)
8.6.3. Market Revenue and Forecast By End-Use, 2015 - 2026 ($Million)
8.7. Rest of Europe
8.7.1. Market Revenue and Forecast By Drug Type, 2015 - 2026 ($Million)
8.7.2. Market Revenue and Forecast By Disease Indication, 2015 - 2026 ($Million)
8.7.3. Market Revenue and Forecast By End-Use, 2015 - 2026 ($Million)
CHAPTER 9. ASIA-PACIFIC CARDIOVASCULAR DRUGS MARKET BY COUNTRY
9.1. Asia-Pacific Cardiovascular Drugs Market Revenue and Growth Rate, 2015 - 2026 ($Million)
9.2. Asia-Pacific Cardiovascular Drugs Market Revenue Share Comparison, 2015 & 2026 (%)
9.3. China
9.3.1. Market Revenue and Forecast By Drug Type, 2015 - 2026 ($Million)
9.3.2. Market Revenue and Forecast By Disease Indication, 2015 - 2026 ($Million)
9.3.3. Market Revenue and Forecast By End-Use, 2015 - 2026 ($Million)
9.4. Japan
9.4.1. Market Revenue and Forecast By Drug Type, 2015 - 2026 ($Million)
9.4.2. Market Revenue and Forecast By Disease Indication, 2015 - 2026 ($Million)
9.4.3. Market Revenue and Forecast By End-Use, 2015 - 2026 ($Million)
9.5. India
9.5.1. Market Revenue and Forecast By Drug Type, 2015 - 2026 ($Million)
9.5.2. Market Revenue and Forecast By Disease Indication, 2015 - 2026 ($Million)
9.5.3. Market Revenue and Forecast By End-Use, 2015 - 2026 ($Million)
9.6. Australia
9.6.1. Market Revenue and Forecast By Drug Type, 2015 - 2026 ($Million)
9.6.2. Market Revenue and Forecast By Disease Indication, 2015 - 2026 ($Million)
9.6.3. Market Revenue and Forecast By End-Use, 2015 - 2026 ($Million)
9.7. South Korea
9.7.1. Market Revenue and Forecast By Drug Type, 2015 - 2026 ($Million)
9.7.2. Market Revenue and Forecast By Disease Indication, 2015 - 2026 ($Million)
9.7.3. Market Revenue and Forecast By End-Use, 2015 - 2026 ($Million)
9.8. Rest of Asia-Pacific
9.8.1. Market Revenue and Forecast By Drug Type, 2015 - 2026 ($Million)
9.8.2. Market Revenue and Forecast By Disease Indication, 2015 - 2026 ($Million)
9.8.3. Market Revenue and Forecast By End-Use, 2015 - 2026 ($Million)
CHAPTER 10. LATIN AMERICA CARDIOVASCULAR DRUGS MARKET BY COUNTRY
10.1. Latin America Cardiovascular Drugs Market Revenue and Growth Rate, 2015 - 2026 ($Million)
10.2. Latin America Cardiovascular Drugs Market Revenue Share Comparison, 2015 & 2026 (%)
10.3. Brazil
10.3.1. Market Revenue and Forecast By Drug Type, 2015 - 2026 ($Million)
10.3.2. Market Revenue and Forecast By Disease Indication, 2015 - 2026 ($Million)
10.3.3. Market Revenue and Forecast By End-Use, 2015 - 2026 ($Million)
10.4. Mexico
10.4.1. Market Revenue and Forecast By Drug Type, 2015 - 2026 ($Million)
10.4.2. Market Revenue and Forecast By Disease Indication, 2015 - 2026 ($Million)
10.4.3. Market Revenue and Forecast By End-Use, 2015 - 2026 ($Million)
10.5. Rest of Latin America
10.5.1. Market Revenue and Forecast By Drug Type, 2015 - 2026 ($Million)
10.5.2. Market Revenue and Forecast By Disease Indication, 2015 - 2026 ($Million)
10.5.3. Market Revenue and Forecast By End-Use, 2015 - 2026 ($Million)
CHAPTER 11. MIDDLE EAST & AFRICA CARDIOVASCULAR DRUGS MARKET BY COUNTRY
11.1. Middle East & Africa Cardiovascular Drugs Market Revenue and Growth Rate, 2015 - 2026 ($Million)
11.2. Middle East & Africa Cardiovascular Drugs Market Revenue Share Comparison, 2015 & 2026 (%)
11.3. GCC
11.3.1. Market Revenue and Forecast By Drug Type, 2015 - 2026 ($Million)
11.3.2. Market Revenue and Forecast By Disease Indication, 2015 - 2026 ($Million)
11.3.3. Market Revenue and Forecast By End-Use, 2015 - 2026 ($Million)
11.4. South Africa
11.4.1. Market Revenue and Forecast By Drug Type, 2015 - 2026 ($Million)
11.4.2. Market Revenue and Forecast By Disease Indication, 2015 - 2026 ($Million)
11.4.3. Market Revenue and Forecast By End-Use, 2015 - 2026 ($Million)
11.5. Rest of Middle East & Africa
11.5.1. Market Revenue and Forecast By Drug Type, 2015 - 2026 ($Million)
11.5.2. Market Revenue and Forecast By Disease Indication, 2015 - 2026 ($Million)
11.5.3. Market Revenue and Forecast By End-Use, 2015 - 2026 ($Million)
CHAPTER 12. COMPANY PROFILE
12.1. Novartis AG
12.1.1. Company Snapshot
12.1.2. Overview
12.1.3. Financial Overview
12.1.4. Product Portfolio
12.1.5. Key Developments
12.1.6. Strategies
12.2. Bayer AG
12.2.1. Company Snapshot
12.2.2. Overview
12.2.3. Financial Overview
12.2.4. Product Portfolio
12.2.5. Key Developments
12.2.6. Strategies
12.3. Pfizer Inc.
12.3.1. Company Snapshot
12.3.2. Overview
12.3.3. Financial Overview
12.3.4. Product Portfolio
12.3.5. Key Developments
12.3.6. Strategies
12.4. Merck and Co. Inc.
12.4.1. Company Snapshot
12.4.2. Overview
12.4.3. Financial Overview
12.4.4. Product Portfolio
12.4.5. Key Developments
12.4.6. Strategies
12.5. Johnson & Johnson
12.5.1. Company Snapshot
12.5.2. Overview
12.5.3. Financial Overview
12.5.4. Product Portfolio
12.5.5. Key Developments
12.5.6. Strategies
12.6. Eli Lilly and Company
12.6.1. Company Snapshot
12.6.2. Overview
12.6.3. Financial Overview
12.6.4. Product Portfolio
12.6.5. Key Developments
12.6.6. Strategies
12.7. Takeda Pharmaceutical Company Ltd
12.7.1. Company Snapshot
12.7.2. Overview
12.7.3. Financial Overview
12.7.4. Product Portfolio
12.7.5. Key Developments
12.7.6. Strategies
12.8. Otsuka Holdings Co., Ltd
12.8.1. Company Snapshot
12.8.2. Overview
12.8.3. Financial Overview
12.8.4. Product Portfolio
12.8.5. Key Developments
12.8.6. Strategies
12.9. Gilead Sciences Inc.
12.9.1. Company Snapshot
12.9.2. Overview
12.9.3. Financial Overview
12.9.4. Product Portfolio
12.9.5. Key Developments
12.9.6. Strategies
12.10. Sun Pharma Industries
12.10.1. Company Snapshot
12.10.2. Overview
12.10.3. Financial Overview
12.10.4. Product Portfolio
12.10.5. Key Developments
12.10.6. Strategies
12.11. Abbott Laboratories
12.11.1. Company Snapshot
12.11.2. Overview
12.11.3. Financial Overview
12.11.4. Product Portfolio
12.11.5. Key Developments
12.11.6. Strategies
12.12. Others
12.12.1. Company Snapshot
12.12.2. Overview
12.12.3. Financial Overview
12.12.4. Product Portfolio
12.12.5. Key Developments
12.12.6. Strategies
CHAPTER 13. RESEARCH APPROACH
13.1. Research Methodology
13.1.1. Initial Data Search
13.1.2. Secondary Research
13.1.3. Primary Research
13.2. Assumptions and Scope
